TEAREVO

Tearevo is a preclinical-stage biotechnology company focused on developing innovative therapies for ocular surface diseases, specifically targeting dry eye disease and neuropathic corneal pain. The company's lead program involves a highly selective, small molecule antagonist of the TRPV1 receptor, designed to address the underlying pain and inflammation associated with chronic eye conditions. By leveraging a deep understanding of corneal neurobiology, Tearevo aims to provide long-lasting relief for patients who do not respond to current standard-of-care treatments. The company is headquartered in the United States and is advancing its pipeline toward IND-enabling studies.